Spring MIT
June 17 - 18
Longwood Healthcare Leaders Spring MIT is co-hosted by MIT Institute Professors Phil Sharp (Nobel laureate) and Bob Langer and held at MIT’s Koch Institute.
Join top biopharma CEOs, heads of R&D, life science investors, and leading academics for two days of top level content
and senior networking at MIT.
Co-hosts:
Featured Speakers
Regulatory & Public Policy Leaders
Academia & Research
BioPharma CEOs
Pharma R&D Leaders
BD & Strategy Leaders
Longwood Portfolio
Venue
Longwood Healthcare Leaders Spring MIT
will be held at MIT’s Koch Institute (500 Main Street, Cambridge, MA) in Cambridge’s Kendall Square.
Koch Institute, 500 Main Street, Cambridge, MA
Agenda
.jpg)
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
8:00 am
(BIG BIO)PHARMA PIPELINE SOURCING
Johanna Bendell, Global Head Oncology, Pharma Research & Early Development, Roche
Francisco Ramirez-Valle, SVP, Head, Research, Bristol Myers Squibb
8:30 am
TRANSLATING SCIENCE INTO MEDICINE
Sek Kathiresan, CEO, Verve Therapeutics
John Lepore, CEO, Profound Therapeutics
Søren Møller, Managing Director, Novo Holdings
Brent Vaughan, CEO, Cognito Therapeutics
Moderator: Teresa Bitetti, President, Global Oncology, Takeda
9:00 am
DRIVING PRODUCTIVITY IN R&D
Ivan Cheung, CEO, NextPoint Therapeutics
Martin Mackay, Chair, RallyBio
Mathai Mammen, CEO, FogPharma
Joanne Smith-Farrell, CEO, Be Bio
Moderator: Yiannis Kiachopoulos, CEO, Causaly
9:30 am
REGULATORY KEYNOTE
Victor Dzau, President, National Academy of Medicine
Peter Marks, Director, CBER, FDA
9:50 am
NETWORKING BREAK
10:20 am
TARGETED LICENSING & ACQUISITIONS
David Meek, former CEO, Mirati Therapeutics
Gilmore O’Neill, CEO, Editas Medicine
Deniz Razon, CBO, Servier Pharmaceuticals
Devyn Smith, CEO, Arbor Bio
Moderator: Caleb Bates, Principal, Fish & Richardson
10:50 am
INNOVATION IN DRUG DISCOVERY
Jeb Keiper, CEO, Nimbus Therapeutics
Frank Laukien, CEO, Bruker
Raj Prasad, CFO, Crispr Therapeutics
Phil Vickers, CEO, Solu Therapeutics
11:20 am
FIRESIDE CHAT
Chris Viehbacher, CEO, Biogen
Phil Sharp, Institute Professor, MIT; Scientific Co-Founder, Biogen
Moderator: Christoph Westphal, General Partner, Longwood Fund
11:40 am
FIRESIDE CHAT
Fidah Alsagoff, Vice Chair, Life Sciences, Temasek
Moderator: Christoph Westphal, General Partner, Longwood Fund
12:00 pm
NETWORKING LUNCHEON
1:00 pm
THE FUTURE OF MENTAL HEALTHCARE
Deborah Dunsire, former CEO, Lundbeck
Guy Goodwin, CMO, COMPASS Pathways
Anne Klibanski, President & CEO, Mass General Brigham
Vikram Sudarsan, CEO, Engrail Therapeutics
1:30 pm
MODERATED KEYNOTE: DRIVING EARLY STAGE INNOVATION AND ENTREPRENEURSHIP
Sally Kornbluth, President, MIT
1:50 pm
NAVIGATING PARTNERSHIPS ACROSS BORDERS
Stefan Laukien, Co-Founder & President, Retroviral Therapeutics
2:20 pm
NETWORKING BREAK
3:00 pm
GETTING TO REGULATORY APPROVAL
Aine Hanly, CTO, Vir Bio
Peter Hutt, former General Counsel, FDA
Moderator: Uma Sharma, CEO, MMS Holdings
3:30 pm
INNOVATIVE COMMERCIAL MODELS
Sharon Benzeno, CCO, Immune Medicine, Adaptive Biotechnologies
Tom Klima, CCO & COO, bluebird bio
Rachid Izzar, EVP, Head, Global Product Strategy & Commercialization, Biogen
Scott Weintraub, SVP, US Business, Alexion, AstraZeneca Rare Disease
Moderator: Jake Sparkman, Manager, Life Science Investments, BXP
4:00 pm
MAINTAINING PATIENT-CENTRIC FOCUS
Meg Alexander, Chief Strategy Officer, Ovid Therapeutics
Kristophe Diaz, Executive Director & CSO, CurePSP
Ed Kaye, CEO, Stoke Therapeutics
4:30 pm
DEVELOPING A STRONG SYNDICATE
Ray Camahort, Partner, Venture Investments, Novo Ventures
Ansbert Gadicke, Managing Partner, MPM BioImpact
5:00 – 7:00 pm
COCKTAIL RECEPTION
Monday, June 17
.png)
.jpg)
Tuesday, June 18
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
David Steinberg, General Partner, Longwood Fund
8:00 am
MODERATED KEYNOTE
Jake Auchincloss, U.S. Representative, Commonwealth of Massachusetts
Moderator: Christoph Westphal, General Partner, Longwood Fund
8:30 am
IDENTIFYING NEXT-GENERATION THERAPEUTICS
Omar Abudayyeh, McGovern Institute Fellow, MIT
Carl Hansen, CEO, Abcellera
Joel Schneider, CEO, Carbon Biosciences
Bill Watt, President, Astellas Venture Management
Moderator: Lisa Ricciardi, CEO, Cognition Therapeutics
9:00 am
INNOVATION IN CLINICAL TRIALS
Brian Alexander, SVP, Pharma R&D, Roche Genentech
Leslie Meltzer, CMO, Orchard Therapeutics
Sarah Sheikh, Head, Global Development & SVP, Neuroscience, Takeda
Joe Stauffer, CMO, Antibe Therapeutics
9:30 am
FIRESIDE CHAT
Rochelle Walensky, Director, CDC (2021-2023)
9:50 am
NETWORKING BREAK
10:20 am
ACCELERATING DRUG DEVELOPMENT
Paul Kingma, Chief Medical Advisor, Myra EB Sytems
Priya Singhal, EVP, Head, Development, Biogen
Moderator: Brian Taylor, CEO, SmartLabs
10:50 am
MANAGING THE RUNWAY
Dror Harats, CEO, ImmuneWalk Therapeutics
Anna Kazanchyan, CEO, Saghmos Therapeutics
Paul Peter Tak, CEO, Candel Therapeutics
Brendan Smith, CEO, Doppler Bio
11:20 am
PLATFORM TO PIPELINE
Geoff McDonough, CEO, Generation Bio
Mittul Mehta, CIO & Head, AI, Tevogen
Zhen Su, CEO, Marengo Therapeutics
Leslie Williams, CEO, HC Bioscience
11:50 pm
FIRESIDE CHAT: PHARMA R&D
Andy Plump, President, R&D, Takeda
Dave Reese, Chief Technology Officer, Amgen
12:10 pm
NETWORKING LUNCHEON
1:00 pm
ADVANCING LATE STATE ASSETS
Al Beardsley, COO, Galera Therapeutics
Brian Goff, CEO, Agios
Caroline Loew, CEO, Mural Oncology
1:30 pm
ENSURING HEALTH EQUITY & ACCESS
Laurie Glimcher, CEO, Dana-Farber Cancer Institute
Pierre Theodore, Executive Director, Patient Impact and Health Equity, Genentech
2:00 pm
FIRESIDE CHAT
Bob Langer, Institute Professor, MIT
2:20 pm
R&D COLLABORATION
Frank DeRosa, Chief Technology Officer, Global Head, Research, mRNA Center of Excellence, Sanofi
Samir Hanash, Department Head, Early Detection and Treatment of Cancer, MD Anderson
Tamer Mohamed, CEO, Aspect Biosystems
2:50 pm
NETWORKING BREAK
3:20 pm
FIRESIDE CHAT
Mikael Dolsten, CSO & President, Worldwide Research, Development & Medical, Pfizer
Christophe Weber, CEO, Takeda
3:40 pm
ECOSYSTEM OF EXTERNAL INNOVATION
Bob Silverman, CBO, Turbine Simulated Cell Technologies
Uli Stilz, VP, Bio Innovation Hub, Novo Nordisk
4:10 pm
INVESTMENT OUTLOOK
Deepak Abraham, CEO, FGEN Ltd
.png)
Speaking Faculty
.jpg)
.jpg)
.png){kind=logo}
.jpg){kind=logo}
